ArticleFrontiers in immunology2026
Editorial: HIV-1 Tat, an enhancer of virus infectivity and disease promoter: target for preventive and therapeutic interventions.
Aurelio Cafaro, Jonathan Karn, Ben Berkhout, Susana Valente, Barbara Ensoli
Abstract readEditorial
In one paragraphArticle in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
5 authors.
Aurelio CafaroNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Jonathan KarnDepartment of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, Cleveland, OH, United States.
Ben BerkhoutLaboratory of Experimental Virology, University of Amsterdam, Amsterdam, Netherlands.
Susana ValenteDepartment of Immunology and Microbiology, University of Florida, Scripps Biomedical Research, Jupiter, FL, United States.
Barbara EnsoliNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Funding
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Immaculate Lillian Nankya · 1994 to 2026
$50.0MHOPE - HIV Obstruction by Programmed EpigeneticsUM1AI164559 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Lishomwa C Ndhlovu, Melanie Maria Ott · 2021 to 2026
$32.2MResearch Support Core D: Clinical and Behavioral ServicesP30DA054557 · NIDA · CASE WESTERN RESERVE UNIVERSITY · PI LEVINE, ALAN DAVID · 2021 to 2025
$16.2MEvaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque modelR01AI167732 · NIAID · UNIVERSITY OF FLORIDA · PI David T Evans, Susana T Valente · 2021 to 2026
$4.3MDevelopment of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuseand Aging on Cognitive ImpairmentR01DA052027 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI NIXON, DOUGLAS F · 2020 to 2024
$3.7MExploration of novel block-and-lock agents alone and in combination for HIV remission in humanized miceR01AI177327 · NIAID · UNIVERSITY OF FLORIDA · PI J. Victor Garcia-Martinez, Susana T Valente · 2023 to 2026
$3.5MHost factors regulating HIV latency and reactivationR37AI165137 · NIAID · UNIVERSITY OF FLORIDA · PI Susana T Valente · 2022 to 2026
$2.0MTherapeutic Disruption of HIV Transcription by HIV-1 Tat Protein-Degrading MoleculesR01AI194820 · NIAID · UNIVERSITY OF FLORIDA · PI Susana T Valente · 2025 to 2026
$2.0MThe role of RNA m6A modification in the regulation of HIV latency and reactivationR33AI169629 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI JONATHAN KARN · 2025 to 2026
$1.4MNIAID NIH HHS P30 AI036219NIAID NIH HHS R01 AI167732NIAID NIH HHS R01 AI177327NIAID NIH HHS R01 AI194820NIAID NIH HHS R33 AI169629NIAID NIH HHS R37 AI165137NIAID NIH HHS UM1 AI164559NIDA NIH HHS P30 DA054557NIDA NIH HHS R01 DA052027
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
AIDS- and non-AIDS-associated morbiditiesanti-Tat antibodiesHIV-1 TatHIV cureHIV reservoirpreventive and therapeutic interventionstransmission
Identifiers
PMID42433353
PMCPMC13350058
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390